Demyttenaere K - Search Results

1

Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.

Demyttenaere K, Detraux J, Racagni G, Vansteelandt K. Demyttenaere K, et al. CNS Drugs. 2019 Jun;33(6):549-566. doi: 10.1007/s40263-019-00625-3. CNS Drugs. 2019. PMID: 31065941

2

Patient satisfaction after electroconvulsive therapy.

Sienaert P, De Becker T, Vansteelandt K, Demyttenaere K, Peuskens J. Sienaert P, et al. Among authors: demyttenaere k. J ECT. 2005 Dec;21(4):227-31. doi: 10.1097/01.yct.0000183268.62735.c0. J ECT. 2005. PMID: 16301882

3

Predictors of patient satisfaction after ultrabrief bifrontal and unilateral electroconvulsive therapies for major depression.

Sienaert PA, Vansteelandt K, Demyttenaere K, Peuskens J. Sienaert PA, et al. Among authors: demyttenaere k. J ECT. 2010 Mar;26(1):55-9. doi: 10.1097/YCT.0b013e3181ac3c8e. J ECT. 2010. PMID: 19458534 Clinical Trial.

4

Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response.

Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J. Sienaert P, et al. Among authors: demyttenaere k. Bipolar Disord. 2009 Jun;11(4):418-24. doi: 10.1111/j.1399-5618.2009.00702.x. Bipolar Disord. 2009. PMID: 19500095 Clinical Trial.

5

Agomelatine: a narrative review.

Demyttenaere K. Demyttenaere K. Eur Neuropsychopharmacol. 2011 Sep;21 Suppl 4:S703-9. doi: 10.1016/j.euroneuro.2011.07.004. Epub 2011 Aug 10. Eur Neuropsychopharmacol. 2011. PMID: 21835598 Review.

6

Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis.

Demyttenaere K, Reines EH, Lönn SL, Lader M. Demyttenaere K, et al. Prim Care Companion CNS Disord. 2011;13(4):PCC.10m01080. doi: 10.4088/PCC.10m01080. Prim Care Companion CNS Disord. 2011. PMID: 22132350 Free PMC article.

7

A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.

Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S. Demyttenaere K, et al. CNS Spectr. 2013 Jun;18(3):163-70. doi: 10.1017/S1092852913000060. Epub 2013 Mar 11. CNS Spectr. 2013. PMID: 23472671

8

Agomelatine in treating generalized anxiety disorder.

Demyttenaere K. Demyttenaere K. Expert Opin Investig Drugs. 2014 Jun;23(6):857-64. doi: 10.1517/13543784.2014.911840. Epub 2014 Apr 28. Expert Opin Investig Drugs. 2014. PMID: 24766542 Review.

9

The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review.

Demyttenaere K, Van Duppen Z. Demyttenaere K, et al. Int J Neuropsychopharmacol. 2019 Feb 1;22(2):85-92. doi: 10.1093/ijnp/pyy052. Int J Neuropsychopharmacol. 2019. PMID: 29961822 Free PMC article. Review.

10

Outcome in depression (II): beyond the Hamilton Depression Rating Scale.

Demyttenaere K, Kiekens G, Bruffaerts R, Mortier P, Gorwood P, Martin L, Di Giannantonio M. Demyttenaere K, et al. CNS Spectr. 2021 Aug;26(4):378-382. doi: 10.1017/S109285292000142X. Epub 2020 May 19. CNS Spectr. 2021. PMID: 32423491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

333 results

Search Page